01Building on published research
Primary–recurrence cohorts
Which clonal relationships persist from primary disease to recurrence?
- Sample starting point
- Paired FFPE with a clear timeline and pathology records.
- Analysis focus
- Single-cell CNA, subclone composition, shared/additional events and candidate evolutionary models.
Validation and design notes
DNA-level validation of candidate CNAs and independent-case replication.
Discuss this direction ↗02Study-design extension
Pre/post-treatment and residual disease
Does treatment change clonal composition, cell state, or both?
- Sample starting point
- Pre/post-treatment FFPE; assess wellDR-seq separately when fresh tissue is available.
- Analysis focus
- Compare clone fractions and CNA events alongside the treatment timeline.
Validation and design notes
Account for regimens, sampling bias and pathology response; not an individual treatment recommendation.
Discuss this direction ↗03Published breast-study foundation
Early lesions and cell-of-origin hypotheses
Which normal-lineage signals are retained by ancestral clones?
- Sample starting point
- Assessed fresh tissue; normal, adjacent and lesion controls where relevant.
- Analysis focus
- Same-cell genomic clones, RNA states and lineage-associated signals.
Validation and design notes
Tissue localization, markers and functional studies; origin signals are hypotheses, not proof.
Discuss this direction ↗04Building on published research
Gene dosage and candidate mechanisms
Which expression programs associate with a CNA-defined subclone?
- Sample starting point
- Fresh tissue suitable for the same-cell workflow, informed by existing findings.
- Analysis focus
- Clone–expression pairing, dosage-associated candidates and validation priorities.
Validation and design notes
Genetic perturbation, protein assays and external cohorts; distinguish association from causation.
Discuss this direction ↗05Exploratory collaboration
Clones and the spatial microenvironment
Where might a candidate clone reside, and which cells surround it?
- Sample starting point
- Annotated tissue and compatible spatial data or adjacent sections.
- Analysis focus
- Candidate clone mapping and neighborhood hypotheses; cross-data association, not automatically same-cell.
Validation and design notes
Clone-specific CNA, FISH or suitable in situ validation of localization.
Discuss this direction ↗06Exploratory collaboration
Organoids and functional validation
Which clones are retained in a model, and how do they change with perturbation?
- Sample starting point
- Organoids or experimental models with matched source tissue, subject to technical assessment.
- Analysis focus
- Tissue–model concordance, clonal selection and candidate-gene experimental design.
Validation and design notes
Use independent replicates and appropriate controls; model drug response is not patient efficacy.
Discuss this direction ↗